Premium
Antiangiogenic treatment as a pre‐operative management of alveolar soft‐part sarcoma
Author(s) -
Conde Nuria,
Cruz Ofelia,
Albert Asteria,
Mora Jaume
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.23241
Subject(s) - alveolar soft part sarcoma , medicine , bevacizumab , tongue , soft tissue , sarcoma , blood cancer , surgery , soft tissue sarcoma , cancer , radiology , chemotherapy , pathology
Alveolar soft‐part sarcoma (ASPS) is a rare tumor. Cure is based solely on radical surgery. The general prognosis is poor. The tongue is an unusual site in adults, but not in children. Tumor removal can cause a severe impact on quality of life, even if reconstruction is possible. ASPS is a highly vascularized tumor and antiangiogenic therapy may have a role. We describe the use of the antiangiogenic combination bevacizumab and celecoxib in the preoperative management of a patient with an ASPS of the tongue. Pediatr Blood Cancer 2011; 57: 1071–1073. © 2011 Wiley‐Liss, Inc.